Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) shot up 19.6% during trading on Wednesday . The stock traded as high as C$0.33 and last traded at C$0.31. 20,804 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 24,911 shares. The stock had previously closed at C$0.26.
Aptose Biosciences Trading Down 8.2 %
The company has a market cap of C$12.06 million, a price-to-earnings ratio of -0.06 and a beta of 1.36. The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05. The firm has a fifty day moving average price of C$0.30 and a 200 day moving average price of C$0.45.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- Vertiv Stock Under Pressure: Is Opportunity Knocking?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MicroStrategy’s 8% Preferred Stock: What Investors Should Know
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Biotechs on the Brink: 2 Stocks With Huge Potential
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
